PDCD1 and neoplasm: Consistent with the role of IL6 in modulating the tumor microenvironment of NSCLC, patients with high levels of circulating IL6 also display more immunosuppressive Tregs than patients with low IL6 levels [165] and exhibit poorer response to anti-PD1/PDL1 immune checkpoint blockade [166,167].